Table 1.
Current clinical studies with LILRB1 targeting antibodies or fusion proteins.
| Antibody/immune construct (company) | Format | Target | Disease | Intervention | Phase | Clinical trials. gov identifier |
|---|---|---|---|---|---|---|
| BND-22/SAR444881 (Biond Biologics/Sanofi) |
humanized IgG4 | LILRB1 | advanced solid tumors | BND-22/SAR444881 alone BND-22/SAR444881 + anti-PD-1 (pembrolizumab) BND-22/SAR444881 + anti-EGFR (cetuximab) |
I/II | NCT04717375 |
| NGM707 (NGM Biopharmaceuticals) |
humanized IgG | LILRB1, LILRB21 | advanced solid tumors | NGM707 alone NGM707 + anti-PD-1 (pembrolizumab) |
I/II | NCT04913337 |
| AGEN1571 (Agenus) |
human IgG4κ | LILRB1, LILRB22 | advanced solid tumors | AGEN1571 alone AGEN1571 + anti-PD-1 (balstilimab) AGEN1571 + anti-CTLA-4 (botensilimab) |
I | NCT05377528 |
| IOS-1002 (ImmunOs Therapeutics) |
Human HLA-β2m-Fc fusion | LILRB1, LILRB2, KIR3DL1 | advanced solid tumors | IOS-1002 alone IOS-1002 + anti-PD-1 |
I | NCT05763004 |
1Weak cross reactivity with LILRB2, 2dual specificity for LILRB1/2.